Abstract
Obesity is becoming one of the major health problems across the world [1]. The risks involved with being overweight or obese are related to the deposition of adipose tissue (adiposity) that is associated with increased risk of adverse health problems. Dosing medications in obese subjects is a challenge as these patients are often excluded from many premarketing clinical drug trials. Current dosage recommendations for most drugs for obese patients are most often inferred from normal-weight persons. As the pharmacokinetics (PK) and pharmacodynamics (PD) of many drugs are altered by the disproportional increase of adiposity relative to lean body mass in morbid obesity, dosing based on total body weight could lead to the risk of overdose and serious clinical complications. An individualised dosing scalar that takes into account the changed body composition should be used in MO patient, particularly in anaesthesia and intensive care.
References
Bjorntorp P. Obesity. Lancet. 1997;350:423–6.
Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond). 2008;32:959–66.
Gallagher D, Visser M, Sepulveda D, et al. How useful is body mass index for comparison of body fatness across age, sex and ethnic groups? Am J Epidermiol. 1996;143:228–39.
Taylor AE, Ebrahim S, Ben-Shlomo Y, et al. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using date form 4 UK cohorts. Am J Clin Nutr. 2010;91:547–56.
Gelber RP, Gaziano JM, Orav EJ, et al. Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol. 2008;52:605–15.
Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustments in the obese patient. Clin Pharmacokinet. 2004;43:1167–78.
Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215–31.
Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.
Vasan KM, Lopez-Berestein G. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res. 1993;24:395–401.
Wada DR, Bjirkman S, Ebling WF, et al. Computer stimulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology. 1997;87:884–99.
Alvarez AO, Cascardo A, Albarracin Menendez S, et al. Total intravenous anesthesia with midazolam, remifentanil, propofol, cisatracurium in morbid obesity. Obes Surg. 2000;10:353–60.
Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology. 1993;78:657–65.
Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender and obesity on midazolam kinetics. Anesthesiology. 1984;61:27–35.
Juvin P, Vadam C, Malek DH, et al. Postoperative recovery after desflurane, propofol or isoflurane anesthesia among morbidly obese patients: a prospective randomized study. Anesth Analg. 2000;91:714–9.
Strum DP, Eger EI. Partition coefficients of desflurane in human blood saline and olive oil. Anesth Analg. 1987;66:971–3.
Arain SR, Barth CD, Shankar H, Ebert TJ. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. J Clin Anesth. 2005;17:413–9.
Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg. 2006;102:438–42.
Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamics effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004;99:1086–9.
Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg. 2004;99:1090–4.
Loupec T, Frasca D, Rousseau N, et al. Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients. Anaesthesia. 2016;71(3):265–72.
Casati A, Putuz M. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth. 2005;17:134–45.
Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996;64:357–64.
Lotsch J, Dudziak R, Freynhagen R, et al. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet. 2006;45:1051–60.
Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists task force on perioperative management of patients with obstructive sleep apnea. Anesthesiology. 2006;104:1081–93.
Kehlet H, Holte K. Effect of postoperative analgesia on surgical outcome. Br J Anesth. 2001;87:62–72.
Von Ungern-Sternberg BS, Regli A, Reber A, Schneider MC. Effect of obesity and thoracic epidural analgesia on perioperative spirometry. Br J Anaesth. 2005;94:121–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Lee, C., Millington, K., Manuel, A. (2018). Drugs and Medications. In: Esquinas, A., Lemyze, M. (eds) Mechanical Ventilation in the Critically Ill Obese Patient. Springer, Cham. https://doi.org/10.1007/978-3-319-49253-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-49253-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-49252-0
Online ISBN: 978-3-319-49253-7
eBook Packages: MedicineMedicine (R0)